Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYD88 mutation
i
Other names:
MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4615
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
(19)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia (NCT05640102)
Phase N/A
BeiGene
BeiGene
Recruiting
Phase N/A
BeiGene
Recruiting
Last update posted :
04/30/2024
Initiation :
03/03/2023
Primary completion :
12/01/2026
Completion :
12/01/2027
MYD88
|
MYD88 mutation • MYD88 L265P • MYD88 wild-type
|
Brukinsa (zanubrutinib)
Ibrutinib + Venetoclax in Untreated WM (NCT04273139)
Phase 2
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Active, not recruiting
Phase 2
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
04/23/2024
Initiation :
07/09/2020
Primary completion :
06/06/2022
Completion :
02/01/2028
BCL2 • MYD88
|
MYD88 mutation
|
Venclexta (venetoclax) • Imbruvica (ibrutinib)
ZR-CHOP in DLBCL With Specific Gene Abnormality (NCT05290337)
Phase 2
Fudan University
Fudan University
Recruiting
Phase 2
Fudan University
Recruiting
Last update posted :
03/22/2022
Initiation :
01/04/2022
Primary completion :
01/04/2024
Completion :
01/04/2026
TP53 • MYC • MYD88 • CD79B
|
TP53 mutation • NOTCH1 mutation • MYD88 mutation • CD79B mutation • CD79B mutation • MYC translocation
|
Rituxan (rituximab) • Brukinsa (zanubrutinib)
Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia (WAL-KU) (NCT02640287)
Phase N/A
Central Hospital, Nancy, France
Central Hospital, Nancy, France
Completed
Phase N/A
Central Hospital, Nancy, France
Completed
Last update posted :
08/06/2021
Initiation :
02/01/2016
Primary completion :
06/01/2020
Completion :
07/01/2020
MYD88
|
MYD88 mutation • MYD88 L265P
Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma (PROTEOM) (NCT04183569)
Phase N/A
University Hospital, Bordeaux
University Hospital, Bordeaux
Unknown status
Phase N/A
University Hospital, Bordeaux
Unknown status
Last update posted :
04/29/2020
Initiation :
02/19/2019
Primary completion :
05/01/2020
Completion :
05/01/2020
BCL2 • CDKN2A • MYD88 • CD79B • TNFAIP3 • PIM1 • PRDM1
|
CDKN2A deletion • MYD88 mutation • CD79B mutation • PIM1 mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login